Team

SpotitEarly’s canine partners are at the heart of its early cancer detection platform. This article explores how the dogs are selected, trained, and cared for, and the science behind their extraordinary ability to detect cancer through scent. Learn about their daily work alongside handlers, the role they play in the hybrid canine-AI detection process, and how their skills contribute to making cancer screening accurate, non-invasive, and accessible.

SpotitEarly welcomed Dr. J. Leonard “Len” Lichtenfeld as its first Chief Medical Officer to help accelerate early cancer detection. This article outlines his career leadership at the American Cancer Society, his vision for catching cancer earlier, and his priorities at SpotitEarly: advancing rigorous clinical research, building partnerships across healthcare, and securing the resources to scale access to innovative, non‑invasive screening worldwide.

As SpotitEarly’s COO and co-founder, Udi Bobrovsky oversees the operational and strategic direction of the company’s early cancer detection platform. In this interview, he shares how his background in tech entrepreneurship and digital health drives the company’s mission, his approach to scaling a hybrid canine-AI screening system, and why he believes innovation and collaboration are key to transforming cancer detection globally.

At the heart of SpotitEarly’s innovation are its partnerships with leading hospitals and research institutions worldwide. This post explains how these clinical collaborations validate the accuracy of its breath-based screening method, integrate with existing protocols, and enhance early cancer detection efforts. Learn how SpotitEarly’s platform works alongside—not against—current standards for better, non-invasive diagnostics.

SpotitEarly is powered by a remarkable team of scientists, engineers, clinicians, and canine specialists, all united by a mission to transform early cancer detection. In this post, meet the innovators behind the test — from the co-founders to the AI developers, dog trainers, and clinical leaders — and learn how their expertise and collaboration make SpotitEarly’s hybrid detection model a global breakthrough in non-invasive cancer screening.